secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001140361-24-015456
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech prioritizes triple combo for HPV+ HNSCC; 75% 36-mo survival in Ph2
------------------------------------------------------------------------------

- Three-year OS of 75% and 75% ORR in ICI-naive advanced HNSCC with PDS01ADC + Versamune HPV + KEYTRUDA.
- ICI-resistant group: 72% 12-month OS and 63% ORR at optimal PDS01ADC dose; median OS ~20 months.
- Full-year 2023 net loss $42.9M ($1.39/sh) vs $40.9M ($1.43/sh) in 2022; cash $56.6M at Dec 31.
- Company raised ~$10.5M net via ATM in Q4 2023 and appointed new CMO and CFO in late 2023/early 2024.
- VERSATILE-003 trial deprioritized; potentially pivotal randomized trial of triple combo expected to start in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/0001140361-24-015456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124015456/ef20025224_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-015456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer